Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Moreau P; Chari A; Oriol A; Martinez-Lopez J; Haenel M; Touzeau C; Ailawadhi S; Besemer B; de la Rubia Comos J; Encinas C; Mateos MV; Salwender H; Rodriguez-Otero P; Hulin C; Karlin L; Sureda Balari A; Bargay J; Benboubker L; Rosiñol L; Tarantolo S; Terebelo H; Yang S; Wang J; Nnane I; Qi M; Kosh M; Delioukina M; Goldschmidt H.